from web site
Trends Pharmacol Sci. 2009 Oct; 30( 10 ):515 -27. doi: 10. 1016/j. tips. 2009. 07.006. Epub 2009 Sep 2. Evaluation. Erratum in: Trends Pharmacol Sci. 2009 Dec; 30( 12 ):609 Campos Air Conditioning, Moreira FA, Gomes FV, Del Bel EA, Guimares FS. Multiple mechanisms associated with the large-spectrum therapeutic capacity of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci.
GPR3, GPR6, and GPR12 as unique molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacol Sin. 2019 Mar; 40( 3 ):300 -308 [7,1] Br T et al. The endocannabinoid system of the skin in health and illness: unique point of views and restorative opportunities. Patterns Pharmacol Sci. 2009; 30( 8 ):411 -420 Lehmann C, Fisher NB, Tugwell B, Szczesniak A, Kelly M, Zhou J.
Clin Hemorheol Microcirc. 2016; 64( 4 ):655 -662 Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
2016 Mar; 15( 3 ):270 -8 Perez-Reyes M, Wingfield M. Letter: Cannabidiol and electroencephalographic epileptic activity. JAMA. 1974 Dec 23-30; 230( 12 ):1635 [10,1] Szaflarski JP, Bebin EM, Cutter G, De, Wolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBDProgram. This Is Noteworthy improves frequency and severity of seizures and reducesadverse occasions in an open-label add-on potential research study.
2018Oct; 87:131 -136 Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos Air Conditioning, Teixeira AL, Hallak JE, Crippa JA. Effects of cannabidiol in the treatment of clients with Parkinson's illness: an exploratory double-blind trial. J Psychopharmacol. 2014 Nov; 28( 11 ):1088 -98 Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK.
Addict Behav. 2013 Sep; 38( 9 ):2433 -6 Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, Curran HV, Morgan CJ. Cannabidiol boosts combination of specific worry termination in human beings. Psychopharmacology (Berl). 2013 Apr; 226( 4 ):781 -92 Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S.
J Psychopharmacol. 2013 Jan; 27( 1 ):19 -27 Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterktter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and relieves psychotic symptoms of schizophrenia. Transl Psychiatry. 2012 Mar 20; 2: e94 Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA.